ATEM Capital Fund LP
ATEM Capital Fund LP is a venture capital fund that invests in breakthrough technologies in Life Sciences.
Business Model:
Revenue: $7.2M
Employees: 2-10
Rankings
Industries / Tags:
Detailed ATEM Capital Fund LP Information
Geographic Data
Address: 445 Park Ave
City: New York
State: NY
Zip: 10022
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Facebook
Twitter
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
ATEM Capital (atemcap.com) is a NY-based Life Sciences investment fund that invests in breakthrough BioPharma / MedTech / Digital Health. Our prioritized therapeutic areas are platform technologies to cure oncology, autoimmune, cardiovascular, neurology diseases, and infections. In the last years, our team had over ten successful co-investments with the leading venture firms of the US and Europe: OrbiMed, Domain Associates, Canaan, ProQuest, LSP, Aisling Capital, MPM, Alta Partners, Frazier, Sofinnova, KPCB, as well as with the corporate venture firms: Pfizer, Roche, J&a;JDC, Novo, etc. Prioritized therapeutic areas are oncology, autoimmune diseases, rare diseases, and neurology. Our team members have extensive hands-on experience in product launches (over 40 products in the US and Europe), investments management (over $30 billion overall investment/liquidity), and exits of venture-backed companies.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 9/2021 | Amolyt Pharma | Series B | 0 |
| 1/2023 | Amolyt Pharma | Series C | 0 |
| 9/2022 | Arpeggio Bio | Series A | 0 |
| 3/2021 | Iridia | Series B | 0 |
| 3/2022 | Triumvira Immunologics | Series A | 0 |
| 3/2022 | Triumvira Immunologics | Series A | 0 |
| 9/2021 | Amolyt Pharma | Series B | 0 |
| 3/2021 | Iridia | Series B | 0 |
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
